Gen-Probe's Michael Watts sees five potential new product launches as delivering top-line growth next year.
Worries about the FDA's ruling on the relative safety of menthol cigarettes have left Lorillard's bonds looking attractively priced according to Morningstar's Dave Sekera.
Aptar COO Steve Hagge on how the firm's close client relationships and FDA-approved dispensers give the firm an advantage in consumer packaging.
Cara Esser explains the fundamentals behind Morningstar's CEF Analyst Ratings and what investors should keep in mind before buying or selling a fund.
©2012 Morningstar Advisor. All right reserved.